Literature DB >> 18473187

Biological and structural analysis of truncated analogs of PACAP27.

Steve Bourgault1, David Vaudry, Laure Guilhaudis, Emilie Raoult, Alain Couvineau, Marc Laburthe, Isabelle Ségalas-Milazzo, Hubert Vaudry, Alain Fournier.   

Abstract

The affinity toward the PAC1 receptor, the biological activity, and the alpha-helical content of several truncated PACAP27 analogs were measured. We first evaluated the pharmacological and structural parameters of C-terminal shortened PACAP fragments, from PACAP(1-23) to PACAP(1-19). All carboxy-truncated derivatives demonstrated circular dichroism spectra typical of a helical conformation. On the other hand, progressive shortening of the C-terminal domain gradually decreases the potency of PACAP to bind and to activate the PAC1 receptor. This decrease in biological activity was mainly attributed to the removal of residues that seem to interact directly with the receptor rather than to a destabilization of the C-terminal helical conformation. We also investigated the pharmacological and conformational characteristics of several hybrid PACAP27 derivatives containing an aliphatic molecular spacer connecting the N-terminal domain to the C-terminal region. However, this strategy revealed that none of these discontinuous analogs showed any significant affinity toward the PAC1 receptor, even if some of them exhibited circular dichroism spectra corresponding to an alpha-helical structure. This study suggests that several domains of PACAP27 are involved in the interaction with the PAC1 receptor and that the presence of the helical conformation is not a sufficient feature for receptor activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473187     DOI: 10.1007/s12031-008-9081-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  32 in total

1.  Conformationally restricted PACAP27 analogues incorporating type II/II' IBTM beta-turn mimetics. Synthesis, NMR structure determination, and binding affinity.

Authors:  R González-Muñiz; M Martín-Martínez; C Granata; E de Oliveira; C M Santiveri; C González; D Frechilla; R Herranz; M T García-López; J Del Río; M Angeles Jiménez; D Andreu
Journal:  Bioorg Med Chem       Date:  2001-12       Impact factor: 3.641

2.  DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data.

Authors:  Lee Whitmore; B A Wallace
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

3.  Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult.

Authors:  David Vaudry; Carol Hamelink; Ruslan Damadzic; Robert L Eskay; Bruno Gonzalez; Lee E Eiden
Journal:  Peptides       Date:  2005-07-11       Impact factor: 3.750

Review 4.  Concepts and progress in the development of peptide mimetics.

Authors:  G L Olson; D R Bolin; M P Bonner; M Bös; C M Cook; D C Fry; B J Graves; M Hatada; D E Hill; M Kahn
Journal:  J Med Chem       Date:  1993-10-15       Impact factor: 7.446

Review 5.  Neuroprotective potential of three neuropeptides PACAP, VIP and PHI.

Authors:  Agnieszka Dejda; Paulina Sokołowska; Jerzy Z Nowak
Journal:  Pharmacol Rep       Date:  2005 May-Jun       Impact factor: 3.024

6.  PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis.

Authors:  D Vaudry; T F Pamantung; M Basille; C Rousselle; A Fournier; H Vaudry; J C Beauvillain; B J Gonzalez
Journal:  Eur J Neurosci       Date:  2002-05       Impact factor: 3.386

7.  Pituitary adenylate cyclase-activating polypeptide prevents cell death in the spinal cord with traumatic injury.

Authors:  Wen-Hsin Chen; Shun-Fen Tzeng
Journal:  Neurosci Lett       Date:  2005 Aug 12-19       Impact factor: 3.046

8.  Conformational and biological studies of neuropeptide Y analogs containing structural alterations.

Authors:  A Fournier; D Gagnon; R Quirion; A Cadieux; Y Dumont; L H Pheng; S St-Pierre
Journal:  Mol Pharmacol       Date:  1994-01       Impact factor: 4.436

9.  Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist.

Authors:  P Robberecht; P Gourlet; P De Neef; M C Woussen-Colle; M C Vandermeers-Piret; A Vandermeers; J Christophe
Journal:  Eur J Biochem       Date:  1992-07-01

10.  C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.

Authors:  P Gourlet; A Vandermeers; M C Vandermeers-Piret; J Rathé; P De Neef; P Robberecht
Journal:  Regul Pept       Date:  1996-04-23
View more
  5 in total

1.  A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.

Authors:  Irene Ramos-Álvarez; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Paola Moreno; Terry W Moody; Jerome L Maderdrut; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-02-16       Impact factor: 3.750

Review 2.  Regulating the ubiquitin/proteasome pathway via cAMP-signaling: neuroprotective potential.

Authors:  He Huang; Hu Wang; Maria E Figueiredo-Pereira
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

Review 3.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146

Review 4.  Targeted Orexin and Hypothalamic Neuropeptides for Migraine.

Authors:  Lauren C Strother; Anan Srikiatkhachorn; Weera Supronsinchai
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

5.  Cell-Penetrating Ability of Peptide Hormones: Key Role of Glycosaminoglycans Clustering.

Authors:  Armelle Tchoumi Neree; Phuong Trang Nguyen; Steve Bourgault
Journal:  Int J Mol Sci       Date:  2015-11-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.